OnePin Peptide Library · Repair & Recovery
Tesa / Ipa Blend
Tesamorelin + Ipamorelin Stack
Tesa / Ipa Blend is a pre-mixed growth hormone secretagogue combination pairing Tesamorelin (the strongest clinically validated GHRH analog) with Ipamorelin (the cleanest GHRP). This blend represents the most evidence-backed GH secretagogue stack available. Tesamorelin is the only GHRH analog with FDA approval (marketed as EGRIFTA SV for HIV-associated lipodystrophy), bringing an unmatched level of clinical data for visceral fat reduction, body composition, liver health, and cognitive support. Paired with Ipamorelin's clean GH-releasing properties, this blend delivers premium GH optimization.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
This blend combines the most clinically validated GHRH analog with the cleanest GHRP for premium dual-pathway GH stimulation:
Tesamorelin
Binds GHRH receptors (GHRH-R) on pituitary somatotrophs with full-length 44-amino acid GHRH sequence, activating cAMP/PKA signaling for GH granule synthesis and release. The trans-3-hexenoic acid modification protects the N-terminus from DPP-IV degradation, extending the signaling window. Unlike CJC-1295 no DAC (a truncated 29-AA fragment), Tesamorelin activates the receptor with the full native sequence, potentially providing more physiologic signaling. Preserves somatostatin feedback for natural pulsatile GH patterns.
Ipamorelin
Binds GHS-R1a (ghrelin receptor) on pituitary somatotrophs through the PLC/IP3/PKC pathway - entirely independent from the GHRH pathway. Selectively releases GH without meaningful cortisol, prolactin, or appetite stimulation. Suppresses somatostatin, removing the natural brake on GH release.
Synergistic Amplification
The GHRH signal (Tesamorelin) and GHRP signal (Ipamorelin) converge through independent intracellular pathways, producing GH pulses 3-5x above baseline. This is the same dual-signal mechanism as CJC/Ipa but with Tesamorelin's stronger, full-length GHRH signal.
Visceral Fat Mechanism
Elevated GH increases lipolysis preferentially in visceral adipose tissue through GH-receptor activation on visceral adipocytes. Tesamorelin clinical trials specifically demonstrated visceral fat reduction with relative preservation of subcutaneous fat. This selectivity is mediated by higher GH receptor density in visceral versus subcutaneous adipose tissue.
Hepatic and Cognitive Effects
GH-mediated IGF-1 elevation reduces hepatic lipogenesis and promotes fatty acid oxidation in the liver. IGF-1 also has direct neurotrophic and neuroprotective effects, supporting the cognitive improvements observed in Tesamorelin clinical trials.
What to expect
Days 1-7: Improved sleep quality and architecture within the first few nights. Mild post-injection sensations (flushing, tingling) are possible but typically gentler than with CJC/Ipa. No appetite change (Ipamorelin is appetite-neutral, Tesamorelin does not stimulate hunger). Mild water retention possible as GH levels rise. IGF-1 begins to elevate.
Weeks 2-8: Body composition changes becoming measurable. Visceral fat reduction beginning (clinical trials showed progressive reduction). Skin hydration and elasticity improving. Recovery from physical activity enhanced. Sleep architecture optimized. Liver enzyme improvements may be detectable on bloodwork for those with elevated baseline values.
Weeks 8-16: Full visceral fat reduction effects approaching clinical trial endpoints. Lean mass gains consolidated. Cognitive improvements (executive function, verbal memory) may be noticeable, consistent with Tesamorelin clinical data in older adults. Skin, hair, and nail quality clearly improved. Consider cycling off after 12-16 weeks with a 4-week break.
Evidence
The honest take
Most clinically validated GH secretagogue combination available
SupportedStrongly supported. Tesamorelin is the only GHRH analog with FDA approval and Phase 3 trial data. Ipamorelin has Phase 1-2 human data. No other GH peptide blend has this level of combined clinical evidence.
Supported by Phase 3 clinical trial data for Tesamorelin monotherapy in HIV lipodystrophy patients. Results in non-HIV populations may differ. The addition of Ipamorelin may enhance or modify this effect, but the combination has not been tested in controlled visceral fat trials.
Preliminary support from a Tesamorelin trial in older adults showing improvements in executive function and verbal memory. Results are from a single study and require replication. Mechanism attributed to IGF-1 neurotrophic effects.
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Safe & synergistic
Keep separate
Side effects & safety
Commonly reported
- Mild injection site reaction (redness, itching) - more common with Tesamorelin than CJC
- Transient flushing or warmth post-injection
- Mild water retention in first 1-2 weeks (subsides)
- Joint stiffness or arthralgias (dose-dependent, from elevated GH/IGF-1)
Less common & notes
- Tesamorelin-specific: injection site reactions are the most commonly reported side effect in clinical trials (up to 8% of patients).
- Peripheral edema and paresthesias can occur at higher doses, reflecting GH-mediated fluid shifts.
- As with all GH-releasing agents, pre-existing malignancy is a contraindication (GH/IGF-1 may promote tumor growth).
- Tesamorelin is contraindicated in pregnancy.
- Ipamorelin does NOT meaningfully elevate cortisol, prolactin, or aldosterone.
- Both components have human safety data, with Tesamorelin having the most extensive clinical trial evidence of any GH peptide.
Pharmacokinetics
Storage. Store lyophilized vial at room temperature or refrigerated. After reconstitution with bacteriostatic water, store refrigerated at 2-8 degrees C. Use within 28-30 days of reconstitution. Tesamorelin is a larger peptide (44 AA) and may be slightly more sensitive to degradation than smaller peptides. Do not freeze after reconstitution. Protect from prolonged light exposure. Discard if solution becomes cloudy or contains particulate matter.
Regulatory status
Tesamorelin is FDA-approved as EGRIFTA SV for HIV-associated lipodystrophy. Ipamorelin has Phase 2 clinical trial data. The pre-mixed blend is a compounding pharmacy product and is not FDA-approved as a combination. Available through compounding pharmacies with prescription. Off-label use for non-HIV body composition, anti-aging, and cognitive support is common but not established by controlled trials in these populations. This is the most clinically validated GH secretagogue combination available.
Put it to work
Calculate, log & track
Open Tesa / Ipa Blend straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Tesa / Ipa Blend in the app →Go deeper
The guide & community
The complete Tesa / Ipa Blend walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗